## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 8 January 2004 (08.01.2004)

PCT

## (10) International Publication Number WO 2004/003565 A2

(51) International Patent Classification<sup>7</sup>:

(21) International Application Number:

G01N 33/68

PCT/EP2003/007006

1 July 2003 (01.07.2003)

(25) Filing Language:

English

(26) Publication Language:

(22) International Filing Date:

English

(30) Priority Data: 02014542.1

1 July 2002 (01.07.2002)

(71) Applicant (for all designated States except US): MY-OCONTRACT LTD [CH/CH]; Hammerstrasse 25, CH-4410 Listal (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MEIER, Thomas [CH/CH]; Wintergasse 10, CH-5065 Basel (CH). JAUSLIN, Matthias [CH/CH]; Klingelberstrasse 33, CH-4056 Basel (CH). SCHOUMACHER, Fabrice [CH/CH]; 20, rue Laparade, F-68440 Eschentzwiller (FR).

(74) Agent: GRÜNECKER, KINKELDEY, STOCKMAIR & SCHWANHÄUSSER; Maximilianstrasse 58, 80538 München (DE).

(81) Designated States (national): CA, US.

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

## Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A SCREENING METHOD AND COMPOUNDS FOR TREATING FRIEDREICH ATAXIA

(57) Abstract: The present invention relates to a method for identifying and/or validating candidate substances for the treatment of Friedreich Ataxia (FRDA). Furthermore, the present invention relates to the use of selenium, Ebselen and Glutathione peroxidase (GPX) mimetics for the preparation of a medicament for the treatment of FRDA. Another aspect of the present invention relates to the use of cells with reduced frataxin expression for identifying and/or validating candidate substances for the treatment of Friedreich Ataxia.